Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2026 08:30 ET | Source: BioMedWire

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure,...
May 27, 2026 08:45 ET | Source: 24/7 Market News

Breakthrough Pipelines Ignite Investor Excitement: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine

Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.
May 15, 2026 10:14 ET | Source: 24/7 Market News

Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism

The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare $HCWB, $TGNT, $MRNA, $REGN
February 04, 2026 09:15 ET | Source: Defiance ETFs

Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.

Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
September 18, 2024 18:48 ET | Source: Robbins LLP

Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline

Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine
August 28, 2024 15:04 ET | Source: Robbins LLP

Shareholder Rights Law Firm Robbins LLP Urges Moderna, Inc. Stockholders to Seek Counsel for the MRNA Class Action

Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine
August 20, 2024 20:08 ET | Source: Robbins LLP

MNRA STOCK NEWS: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Moderna, Inc. Class Action

Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine
August 14, 2024 13:11 ET | Source: Robbins LLP

Stockholder Alert: Robbins LLP Informs Moderna, Inc. Stockholders that a Shareholder Filed a Class Action Against MRNA

Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine
May 27, 2020 14:25 ET | Source: Portnoy Law

Moderna, Inc. Investors: Company Investigated by the Portnoy Law Firm

LOS ANGELES, May 27, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Moderna, Inc. ("Moderna") (NASDAQ: MRNA) investors that the firm has initiated an investigation into possible securities...